Related Experiment Video
Updated: Jul 27, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Statistical considerations for noninferiority/equivalence trials in vaccine development
W W B Wang1, D V Mehrotra, I S F Chan
1Clinical Biostatistics, Merck Research Laboratories, North Wales, Pennsylvania 19454, USA. William_Wang@Merck.Com
Noninferiority and equivalence designs in vaccine trials demonstrate new vaccines are as effective as existing ones. These statistical methods are crucial for vaccine development, ensuring efficacy while offering benefits like improved safety or easier administration.
Area of Science:
- Biostatistics
- Vaccinology
- Clinical Trials
Background:
- Noninferiority/equivalence designs are vital in vaccine clinical trials.
- These designs assess if new vaccines match existing ones in effectiveness.
- Advantages include easier manufacturing, administration, lower cost, or improved safety.
Purpose of the Study:
- To provide an overview of statistical issues and recent developments in noninferiority/equivalence vaccine trials.
- To cover key aspects of trial design and analysis.
- To highlight the application in various immunogenicity trial types.
Main Methods:
- Selection of appropriate study endpoints.
- Formulation of null and alternative hypotheses.
- Determination of the noninferiority/equivalence margin.
- Efficient statistical analysis methods, including adjustments for stratification and missing data.
- Sample size and power calculations.
Main Results:
- The paper outlines critical statistical considerations for designing and analyzing vaccine trials.
- It emphasizes methods for ensuring robust comparisons between new and existing vaccines.
- Recent developments in statistical approaches are discussed.
Conclusions:
- Effective application of noninferiority/equivalence designs requires careful attention to statistical methodology.
- These designs are essential for evaluating new vaccines efficiently and reliably.
- The discussed statistical issues are key to successful vaccine development and regulatory approval.
More Related Videos
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
06:28E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Related Concept Videos
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Equivalence: In Vitro and In Vivo Bioequivalence
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
Bioequivalence studies: Biowaivers
Bioequivalence Data: Statistical Interpretation